@Schwerms no I can't find any detail, However, on the $BOT website I found the following:

"H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction."

They also acted for $BOT in the equity raising. So, I should have mentioned that they are $BOT's IB. They appear to have had $BOT's mandate since mid-2023.

So makes sense they would have an aggressive PT. And also makes sense they would publicise/update a PT at a time of SP weakness!

I can't find any research report or summary.

Thanks @mikebrisy that's about all I could find as well.

While on the Bot topic,

For what it's worth I did a traffic search on similar web (made a trial account) prompted by some numbers I saw on HC..

And for may for visits to getsofdra.com (the upscript site) when I flick it onto engaged visits (more than 1 page viewed) it gives an average site visit duration of 13minutes for approx 3000 people in May.

This is the telehealth website and you would think a decent amount of people of that 3000 could be receiving a script if 13min is the average time on site, There's no data beyond that but it looks like if they turned it on in May ( Matt in the interview on SM seemed to say they didn't do much with it in April) then it could possibly support the debt facility due to the higher cost per user to acquire.. assuming it was similar in June.

Hopefully there's is some correlation in the sales data end of July that may prove this to be useful data in the future.

Disc: not one of my areas of expertise

@Schwerms that's a nice piece of digging!

Yes, the May uptick is completely consistent with the telehealth launch. The average of 13 minutes is also promising. A typical telehealth session is only 10-15 minutes, although there may be some time on the site waiting to see the HCP (can be significant).

Also, the average will include those who didn't stay for the consultation and probably clicked away within a minute or so, and so the value to 13 minutes indicates a decent proportion did stay for the consultation.

It will be interesting to see what the June number looks like? I wonder how soon after month end they become available?

I did a Google trends comparison between Sofdra and Qbrexa (the other anticholinergic available in the US) and below is the US trend over the last 12 months,

Of course, this probably has little relationship to the telehealth platform activity, as it is based on Google searches using the terms "Sofdra" and "Qbrexa". However, it shows Sofdra's online presence become detectable at the launch in February.

Also, it clearly shows the impact of $BOT marketing excellence, achieving a far greater online presence than Qbrexa, which has been on the market for some 4 years already.

I guess we're all spinning our wheels, waiting for the next hard sales data!

Disc: Held

I received this this morning, normally ignore analyst rating noise, but in this case it's worth noting that a new analyst is covering BOT and both have an Outperform rating: